January 30, 2013

Article - Why Pharmacy Compounding Has and Continues to be a Medical Necessity


Why Pharmacy Compounding Has and Continues to be a Medical Necessity

Providing a Solution to Drug Shortages: Compounding

In recent years, healthcare professionals and patients have had to deal with the growing problem of drug shortages, which seriously affect the vital category of sterile injectable drugs. According to the United States Food and Drug Administration (FDA), in 2010 there were 178 drug shortages of which 132 were sterile injectable drugs, and in 2011 those numbers increased to 251 drug shortages of which 183 were sterile injectable drugs.[1]  These shortages sometimes affect whole classes of drugs including essential drugs for cancer treatment, cardiovascular disease, and pain management.  Causes primarily include issues in production quality and manufacturing.  According to the American Society of Health-System Pharmacists, the end result for patients is that drug therapy may be adversely affected, medical procedures may be compromised or delayed, and medication errors may occur.[2]  Compounding provides one solution to solving drug shortages. 
Compounding pharmacies and pharmacists have been and continue to be called upon by patients, healthcare providers, and hospitals to compound medications that are commercially unavailable.   Compounding pharmacies are able to fulfill this need because they have access to the raw materials and the technical expertise required to formulate the needed medications.  Patients can contact compounding pharmacies directly to find prescribed medications that are in short supply, healthcare providers can utilize compounding pharmacies for drugs that are unavailable elsewhere, and hospitals can utilize compounding for intravenous admixtures when the supply of key injectable drugs is unavailable. The demand for compounded medications shows how essential compounding has been and continues to be—particularly in the case of drug shortages. 
In addition to the FDA drug shortages, there are many reasons why compounding continues to be a medical necessity and is an essential part of the healthcare system.  Even though many drugs are not on the FDA drug shortage list, available supplies can still be limited.  Manufacturers produce limited dosage forms, limited strengths, and often discontinue older drugs as they lose market share to produce newer and more profitable drugs.  Compounding is needed when drugs are not available in the needed combinations or when drugs need to be repackaged into the correct dose.  Treating rare medical conditions often requires small supplies of compounded orphan drugs.  Compounding is needed for pediatric formulations, geriatrics formulations, parenteral nutrition, cancer chemotherapy, pain management, and bioidentical hormone replacement therapy.  Diagnosing and treating diseases can be done using nuclear compounding. Compounding is needed for home healthcare, hospice, dental, dermatological, and ophthalmological patients.  When patients cannot tolerate the commercially available product due to non-intrinsic characteristics—such as dyes, preservatives, ethanol, flavor, dosage or delivery method—compounding readily resolves the issue.  The reasons why compounding is needed are endless, but, as a whole, compounding allows accessibility to medications that are not easily available and provides flexibility for patients to receive individualized care according for their health needs.
Compounding pharmacies have always been in the background working to help meet patient needs.  Recently compounding has gained national attention due to the meningitis outbreak stemming from the New England Compounding Center (NECC) in Framingham, Massachusetts. As of the end of November 2012, contaminated spinal injections of methlyprednisolone acetate prepared by NECC have sickened several hundred people and killed more than 30 in multiple states.  Due to the serious problems at NECC, Ameridose, an FDA registered manufacturer with the same founders as NECC, has voluntarily recalled all of its products.[3]  The shutdown of these facilities has only exacerbated the problem of drug shortages, which means that additional demand may be placed upon compounding pharmacies to remedy the situation.
The recent meningitis crisis may have negatively affected the field of compounding even though NECC was not a compounding pharmacy but rather a drug manufacturer.  This distinction is important to note because compounders work in a triad of patient, physician, and pharmacist relationship that helps to ensure the safety of the medications for the patient.  Drug manufacturers mass produce medications without taking into account the individualized needs of the patient. Drug manufacturers are not compounders, and more oversight is needed by the FDA to ensure patient safety when drug manufacturers masquerade as compounding pharmacies. Despite the recent news, there are many healthcare providers and patients that recognize the importance of and the need for compounding.  Moving forward, compounding pharmacists can use the spotlight of the meningitis outbreak to educate the general public that compounding is safe, effective, and an essential medical necessity, especially when faced with drug shortages. 



[1] Frequently asked questions about the drug shortage.  Food and Drug Administration Web Site. 
  http://www.fda.gov/Drugs/DrugSafety/DrugShortages/ucm050796.htm.  Updated August 24, 2012.  Accessed 
  November 21, 2012.
[2] Drug shortages.  American Society of Health-System Pharmacists Web Site.  https://www.ashp.org/shortages.   
  Accessed November 21, 2012.
 [3] Moyer CS.  Drug shortages worsen following pharmacy-related meningitis scare.  American Medical News.  
  December 10, 2012.  http://www.ama-assn.org/amednews/2012/12/10/hlsa1210.htm.  Accessed December 21,   
  2012.


January 26, 2013

Conferences & Meetings - Cold Night/Hot Topic The Meningitis Disaster


Special Event
Cold Night/Hot Topic – The Meningitis Disaster:  How Compounding Practices May Change the Roles and Responsibilities of Pharmacists – 1/24/2013

 

Over winter break a few of our professors at the University of Iowa College of Pharmacy organized an event to discuss in detail the compounding disaster at the New England Compounding Center.  As part of the event, I heard lectures on legal issues in pharmacy compounding, drug shortages, pharmaceutical manufacturing and quality, standards of practice in compounding pharmacy, issues in pain pharmacotherapy, and issues in drug product quality of compounding injectable steroids.  It was interesting to learn the thought process that goes behind injectable drugs and where along the spine the drugs should be injected to minimize the harm to the patient. Also, I learned about the drug shortages that the University of Iowa Hospitals and Clinics are facing and how they handle providing great patient care when faced with the drug shortages. I also heard from a compounding pharmacist who discussed the standard of practice in compounding and the PCAB accreditation that ensures that the drug products are compounded correctly.  It was a great event and I learned a lot about compounding.